Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
No case yet. It builds on the next filing, report or 13F period.
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.
tall tick = annual report · 1 on record
Veraxa Biotech AG - Post de-SPAC has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
High 1.50 at 9:30 am ET, low 1.47 at 1:00 pm ET.
Veraxa Biotech Holding AG
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
8 managers report a position worth $909,430 between them, and 3 of them hold 80% of it.
VRXA (Veraxa Biotech Holding AG) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.